Journal List > J Gynecol Oncol > v.29(6) > 1148301

TOOLS
Son, Chang, and Ryu: ASGO 5th International Workshop on Gynecologic Oncology
Meeting Report

J Gynecol Oncol 2020;29(6):e101.

Published online: 4 November 2020

DOI: https://doi.org/10.3802/jgo.2020.29.e101

ASGO 5th International Workshop on Gynecologic Oncology

Joo-Hyuk Son, Suk-Joon Chang, Hee-Sug Ryu

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea

Correspondence to Suk-Joon Chang Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon 16499, Korea. E-mail: drchang@ajou.ac.kr

Received 8 September 2018       Accepted 8 September 2018

Copyright © 2020 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fig. 1.
The 14th Asian Society of Gynecologic Oncology council meeting. (from left to right) Hextan Ngan,1 Sarikapan Wilailak,2 Daisuke Aoki,3 Ikuo Konishi,4 Toshiharu Kamura,5 Hee-Sug Ryu,6 Soon-Beom Kang,7 Joo-Hyun Nam,8 Neerja Bhatla,9 Ting-Chang Chang,10 Dong Hoon Suh,11 Chunling Chen,12 Suk-Joon Chang,13 David Tan,14 Suresh Kumarasamy,15 Duk-Soo Bae,16 Nobuo Yaegashi,17 Kung-Liahng Wang,18 Seung-Cheol Kim,19 Andri Andrijono,20 Efren Domingo,21 Jiheum Paek,22 Rongyu Zang,23 and Jae-Weon Kim.24
jgo-29-e101f1.tif
Fig. 2.
The 4th Journal of Gynecologic Oncology editorial board meeting. (from left to right) Jeong-Yeol Park,1 Chulmin Lee,2 Dong Hoon Suh,3 Jae-Weon Kim,4 Mi Kyung Kim,5 Dae-Hoon Jeong,6 Ju-won Roh,7 Sun Joo Lee,8 ZheZhu Gao,9 Hidemichi Watari,10 Jatupol Srisomboon,11 Sung Jong Lee,12 Chunling Chen,13 Xiaojun Chen,14 Takayuki Enomoto,15 David Tan,16 Ting-Chang Chang,17 Myong Cheol Lim,18 Se-Ik Kim,19 Jaeyun Song,20 Jung Yun Lee,21 Kyung-Jin Min,22 Yusuke Kobayashi,23 Min Chul Choi,24 Maria Lee,25 Miseon Kim.26
jgo-29-e101f2.tif
Table 1.
Registration by country/region
Rank* Country No. of participant
1 Korea 165
2 Japan 26
3 China 14
4 Thailand 11
5 India 9
6 Indonesia 8
7 Malaysia 6
8 Philippines 5
9 Taiwan 5
10 Hong Kong 2
11 USA 2
12 Bangladesh 1
13 Mongolia 1
14 Myanmar 1
15 Singapore 1
Total   257

* Ordered firstly by the number of participants and then alphabetically among countries with the same number.

Table 2.
Program of ASGO 5th International Workshop on Gynecologic Oncology (day 1)
Schedule Speaker
Welcome address (President of ASGO) Hee-Sug Ryu (Korea)
Congratulatory address (Immediate Past President of ASGO) Ikuo Konishi (Japan)
Congratulatory address (President of KSGO) Young-Tak Kim (Korea)
A-1: Cervical cancer Chair: Daisuke Aoki (Japan), Warner Huh (USA)
    A1–01 Effectiveness of national HPV vaccination program for Japanese young women Takayuki Enomoto (Japan)
    A1–02 All about trachelectomy Jin Li (China)
    A1–03 Revisiting Sedlis criteria: can we do better? Kenneth Kim (USA)
    A1–04 Is MIS the real culprit in poor prognosis of early-stage cervical cancer? Tae-Wook Kong (Korea)
    A1–05 Nodal staging surgery in LACC Seung-Hyuk Shim (Korea)
A-2: Epithelial ovarian cancer Chair: Ikuo Konishi (Japan), Jae-Weon Kim (Korea)
    A2–01 Endometriosis-associated ovarian cancer and associated comorbidity Peng-Hui Wang (Taiwan)
    A2–02 Venous thromboembolism in ovarian cancer patients at Siriraj Hospital Suwanit Therasakvichya (Thailand)
    A2–03 Drug repositioning strategy for ovarian cancer Yusuke Kobayashi (Japan)
    A2–04 Role of PARP inhibitors in ovarian cancer patients Maria Lee (Korea)
    A2–05 BRCA 1/2 mutation-related ovarian cancer in China Tingyan Shi (China)
Roche sponsored session Chair: Chunling Chen (China)
    S1 Platinum-sensitive recurrent ovarian cancer: current practice & future outlook Shin-Wha Lee (Korea)
A-3: Guidelines & position statement Chair: Toshiharu Kamura (Japan), Soon-Beom Kang (Korea)
    A3–01 Introduction Mikio Mikami (Japan)
    A3–02 The current situation of the guidelines on gynecological cancers in Japan Satoru Nagase (Japan)
    A3–03 Koran guidelines & position statement Myong Cheol Lim (Korea)
    A3–04 Chinese guidelines & position statement Jianliu Wang (China)
    A3–05 Thailand guidelines & position statement Sarikapan Wilailak (Thailand)
    A3–06 Essence & future direction on guidelines & position statement development in Asia Mikio Mikami (Japan)
Olympus sponsored session Chair: Byoung-Gie Kim (Korea)
    S2 3D laparoscopic surgery in gynecologic cancer Sang Wun Kim (Korea)
A-4: Chemotherapy/target agents and beyond Chair: Nobuo Yaegashi (Japan), Duk-Soo Bae (Korea)
    A4–01 Current standard of chemotherapy in ovary cancer Sook Hee Hong (Korea)
    A4–02 Targeting DNA-damage repair deficiency David Tan (Singapore)
    A4–03 Immunotherapy in gynecologic oncology: what next? Masaki Manda (Japan)
    A4–04 HIPEC for ovarian cancer: investigational vs. standard of care Suk-Joon Chang (Korea)
    A4–05 Therapeutic stratification based on gene expression subtypes in ovarian cancer Ruby Huang (Singapore)

3D, 3-dimensional; ASGO, Asian Society of Gynecologic Oncology; HIPEC, hyperthermic intraperitoneal chemotherapy; HPV, human papillomavirus; KSGO, Korean Society of Gynecologic Oncology; LACC, locally advanced cervical cancer; MIS, minimally invasive surgery; PARP, poly (ADP-ribose) polymerase.

Table 3.
Program of ASGO 5th International Workshop on Gynecologic Oncology (day 2)
Schedule Speaker
A-5: Clinical trials in Asia Chair: Kazunori Ochiai (Japan), Yong Man Kim (Korea)
    A5–01 Cervical cancer clinical trials in Asia Kimio Ushijima (Japan)
    A5–02 Ovarian cancer clinical trials in Asia Jung-Yun Lee (Korea)
    A5–03 Endometrial cancer clinical trials in Asia Xiaojun Chen (China)
    A5–04 Clinical trials in Asia/AGOG perspective Kazunori Ochiai (Japan)
    A5–05 How to promote collaboration in Asia? Taek Sang Lee (Korea)
A-6: Junior session Chair: Andri Andrijono (Indonesia), Joong Sub Choi (Korea)
    A6–01 Effect of megestrol acetate combined with metformin versus megestrol acetate in women undergoing conservative therapy for atypical hyperplasia or endometrial cancer Bingyi Yang (China)
    A6–02 Intraoperative consultation (frozen section) in the diagnosis of ovarian masses Farhana Kalam (Bangladesh)
    A6–03 A20-mediated deubiquitination of Era in the microenvironment of CD163+ macrophages sensitizes endometrial cancer cells to estrogen running title: macrophages stabilize Era via A20 mediated deubiquitination Qiaoying Lv (China)
    A6–04 Uterine carcinosarcomas: a 6 yr review of cases at a tertiary cancer care institute in India Divya Sehra (India)
    A6–05 A 5-year retrospective review of cases at a tertiary cancer care institute in India Mohd Faizal Ahmad (Malaysia)
    A6–06 Management of endometrial cancer in Adam Malik Hospital Medan, north Sumatra, Indonesia Muhammad Rizki Yaznil (Indonesia)
    A6–07 Analysis of the predictive role of lymph node density, negative lymph node and LODDS on the survival of cervical cancer patients Kanika Batra Modi (India)
    A6–08 Prevalence of anal intraepithelial neoplasia in women with cervical intraepithelial neoplasia Manatsawee Manopunya (Thailand)
Special session Chair: Yoon Soon Lee (Korea)
    S3 HPV vaccine update Dae Hoon Jeong (Korea)
A-7: Endometrial cancer Chair: Hextan Ngan (Hong Kong), Seok Ju Seong (Korea)
    A7–1 Current standard of care and debating points in endometrial cancer Arb-aroon Lertkhachnonsuk (Thailand)
    A7–2 Imaging update in endometrial cancer Hyun Hoon Chung (Korea)
    A7–3 Sarcoma update Hidemichi Watari (Japan)
    A7–4 MSI in endometrial cancer Seob Jeon (Korea)
Closing address (Chair of Organizing Committee) Seung-Cheol Kim (Korea)

AGOG, Asian Gynecologic Oncology Group; HPV, human papillomavirus; LODDS, log odds of positive lymph node; MSI, microsatellite instability.

TOOLS
Similar articles